Sugi Predict

Sugi Predict / Compounds / SCHEMBL391965

SCHEMBL391965

SCHEMBL391965

COCCC(N)c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADRB2 P07550 1/20 0.48
▸ SCN4A P35499 3/20 0.43
▸ AOC3 Q16853 2/20 0.43
▸ IDO1 P14902 2/20 0.41
▸ TDO2 P48775 2/20 0.41
▸ SLC6A3 Q01959 3/20 0.41
▸ SLC6A4 P31645 3/20 0.41
▸ SLC6A2 P23975 2/20 0.41
▸ SLC2A1 P11166 1/20 0.40
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ ESR2 Q92731 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460859 0.86 SCN4A (0.53) ADRB2SCN4AAOC3IDO1TDO2
SCHEMBL5462262 0.86 SCN4A (0.53) ADRB2SCN4AAOC3IDO1TDO2
SCHEMBL28428096 0.82 SLC6A4 (0.41) ADRB2AOC3IDO1TDO2SLC6A3
SCHEMBL6868397 0.80 CYP1A2 (0.61) AOC3SLC6A4SLC2A1CYP1A2CYP2D6
SCHEMBL24581626 0.80 ESR1 (0.42) SLC6A3SLC6A2SLC2A1CYP1A2CYP2D6
SCHEMBL16649569 0.79 SLC6A2 (0.46) IDO1TDO2SLC6A3SLC6A4SLC6A2
SCHEMBL27228890 0.79 SLC6A2 (0.46) IDO1TDO2SLC6A3SLC6A4SLC6A2
SCHEMBL19312226 0.79 SCN4A (0.48) SCN4A
SCHEMBL90024 0.79 SCN4A (0.48) SCN4A
SCHEMBL9198692 0.79 ADRB2 (0.52) ADRB2SCN4AAOC3IDO1TDO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12252495-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2025-03-18 — — US disclosed
US-20240109902-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2024-04-04 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-11760760-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2023-09-19 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-20220220116-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2022-07-14 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-11236095-B2 Protein kinase B inhibitors ASTRAZENECA AB (SE) 2022-02-01 — — US disclosed
US-20200239483-A1 PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2020-07-30 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
US-8101623-B2 Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor ASTRAZENECA AB (SE) 2012-01-24 — — US disclosed
CN-101861321-A Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors ASTRAZENECA AB 2010-10-13 — — CN disclosed
EP-2201012-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS AstraZeneca AB (SE) 2010-06-30 — — EP disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 ASTRAZENECA AB (SE) 2009-06-25 — — US disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed
WO-2009047563-A1 PYRROLO [2, 3 -D] PYRIMIDIN DERIVATIVES AS PROTEIN KINASE B INHIBITORS ASTRAZENECA AB (SE) 2009-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12252495-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885
US-20220220116-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885
US-20240109902-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885
US-20090163524-A1 Novel Protein Kinase B Inhibitors - 060 PRKAR2B, PRKCB, MAP3K20 ADRB2 1387/4885SCN4A 2567/4885AOC3 4865/4885
US-20200239483-A1 PROTEIN KINASE B INHIBITORS PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885
US-11236095-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885
US-11760760-B2 Protein kinase B inhibitors PRKAR2B, PRKCB, AKT1 ADRB2 1451/4885SCN4A 3118/4885AOC3 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.